Prognostic value of FOXA1 in estrogen receptor-negative breast cancer: A systematic review and meta-analysis
PLOS One · 21.10.2025 · 20 (10) · e0332516
DOI: 10.1371/journal.pone.0332516 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS One, online erschienen am 21.10.2025. Verfasst von Angela V Fonseca-Benitez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Hepatocyte Nuclear Factor 3-alpha, Receptors, Estrogen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the Promotion of Research and Technology - Banco de la República, Ministerio de Ciencia, TecnologÃa e Innovación de Colombia.
Abstract (Originalsprache)
Breast cancer remains the most common cancer among women worldwide, and recurrence rates stay high despite current treatments, especially for those with negative estrogen receptor status, where therapies are less effective, and prognosis is worse. Identifying molecules with predictive value for therapy response and prognosis is therefore crucial. In this context, FOXA1 could serve as a potential biomarker to predict the progression of ER-negative tumors. A search was conducted to answer the question, “What is the prognostic value of FOXA1 expression in breast cancer, estrogen receptor negative?” using various databases. Controlled vocabulary and Boolean operators were employed. Only studies reporting overall survival and disease-free survival, defined as the time from evaluation to death or relapse, were included. We identified seven articles evaluating FOXA1 and its relationship with disease-free survival (DFS) or overall survival (OS) in patients with ER-negative breast cancer. Our data indicate that higher FOXA1 expression is associated with improved overall survival (HR = 0.61, CI = 0.45–0.83, p < 0.002) and better disease-free survival (HR = 0.69, CI = 0.51–0.93, p < 0.02). These findings suggest that FOXA1 is linked to a favorable prognosis in terms of overall survival and disease-free survival. Further studies are needed to assess the role of FOXA1 in response to chemotherapy. PROSPERO registration number: CRD42024453750
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
- Universidad El Bosque, School of Dentistry, Bogotá, Colombia.
- Universidad El Bosque, School of Dentistry, Unit of Basic Oral Investigation - UIBO, Bogotá, Colombia.
- Universidad El Bosque, Facultad de Ciencias, INQA-Química Farmacéutica, Bogotá, Colombia.
- School of Biological Sciences, Universidad Pedagógica y Tecnológica de Colombia, Tunja, Colombia.
ORCID-Profile: Angela V Fonseca-Benitez, James Guevara-Pulido, Nelson Rangel
Förderung
- Foundation for the Promotion of Research and Technology - Banco de la República
- Ministerio de Ciencia, TecnologÃa e Innovación de Colombia
Zitieren
APA
Fonseca-Benitez, A. V., Díaz-Báez, D., Guevara-Pulido, J., Rondón-Lagos, M., Aristizábal-Pachón, A. F., & Rangel, N. (2025). Prognostic value of FOXA1 in estrogen receptor-negative breast cancer: A systematic review and meta-analysis. PLOS One, 20(10), e0332516. https://doi.org/10.1371/journal.pone.0332516
Vancouver
Fonseca-Benitez AV, Díaz-Báez D, Guevara-Pulido J, Rondón-Lagos M, Aristizábal-Pachón AF, Rangel N. Prognostic value of FOXA1 in estrogen receptor-negative breast cancer: A systematic review and meta-analysis. PLOS One. 2025;20(10):e0332516. doi:10.1371/journal.pone.0332516
BibTeX
@article{FonsecaBenitez2025,
author = {Fonseca-Benitez, Angela V and Díaz-Báez, David and Guevara-Pulido, James and Rondón-Lagos, Milena and Aristizábal-Pachón, Andrés Felipe and Rangel, Nelson},
title = {Prognostic value of FOXA1 in estrogen receptor-negative breast cancer: A systematic review and meta-analysis},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0332516},
doi = {10.1371/journal.pone.0332516}
}
EUVIMED